Source comparison
Research Dosing Protocols: Single vs Combined Administration
Research applications of CJC-1295 no DAC & Ipamorelin dosage protocols fall into two primary categories: monotherapy (single peptide) and combination therapy (both peptides co-administered). Monotherapy protocols typically employ 200-300mcg of CJC-1295 no DAC
This comparison does not assign a generated winner or score.
- Research applications of CJC-1295 no DAC & Ipamorelin dosage protocols fall into two primary categories: monotherapy (single peptide) and combination therapy (both peptides co-administered). Monotherapy protocols typically employ 200-300mcg of CJC-1295 no DAC or 200-300mcg of Ipamorelin administered 2-3 times daily, targeting the body's natural GH pulse windows. Upon waking, post-training, and before sleep. The timing aligns with circadian patterns: endogenous GH secretion peaks approximately 60-90 minutes after sleep onset and shows secondary pulses following physical exertion and during the early waking hours.
- Combination protocols reduce individual peptide doses to 100-200mcg each per administration due to the synergistic amplification effect. When administered together, CJC-1295 no DAC and Ipamorelin produce GH secretion levels 3-5 times higher than baseline, compared to 2-3 times elevation with either peptide alone at equivalent doses. This synergy allows researchers to achieve target outcomes with lower absolute peptide quantities, reducing cost per protocol cycle while minimizing potential side effects associated with excessive GH stimulation.
- The CJC1295 Ipamorelin 5MG 5MG blend from Real Peptides provides both peptides in equal concentrations, simplifying reconstitution and reducing the number of vials required for combination protocols. Each vial contains 5mg of CJC-1295 no DAC and 5mg of Ipamorelin in lyophilised powder form, manufactured through small-batch synthesis with exact amino-acid sequencing to guarantee purity above 98% as verified by HPLC (high-performance liquid chromatography) and mass spectrometry.
- Dosing frequency matters as much as dose quantity. CJC-1295 no DAC's short half-life. Significantly shorter than the DAC (Drug Affinity Complex) version, which extends half-life to approximately 6-8 days. Requires multiple daily administrations to maintain therapeutic plasma concentrations. Research protocols commonly employ a three-dose schedule: morning (fasted state), post-training (to capitalize on exercise-induced GH pulse potentiation), and pre-sleep (aligning with the body's largest endogenous GH surge). Skipping the pre-sleep dose eliminates coverage during the peak natural secretion window, reducing overall protocol efficacy by an estimated 30-40%.
- Ipamorelin's selectivity for the GHSR-1a receptor without significant ACTH (adrenocorticotropic hormone) or cortisol elevation distinguishes it from earlier ghrelin mimetics like GHRP-2 and GHRP-6, which demonstrate broader receptor activity and corresponding side effects including hunger stimulation and stress hormone increases. In comparative studies, Ipamorelin produced GH secretion levels comparable to GHRP-2 but with cortisol levels remaining within baseline range. A critical distinction for protocols extending beyond 8-12 weeks where chronic cortisol elevation could compromise metabolic outcomes.